Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACHV NASDAQ:LXRX NASDAQ:RIGL NASDAQ:VSTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHVAchieve Life Sciences$3.45+3.9%$2.90$1.84▼$5.31$169.67M1.58838,182 shs810,834 shsLXRXLexicon Pharmaceuticals$1.43-5.9%$1.19$0.28▼$2.18$552.37M1.232.67 million shs3.06 million shsRIGLRigel Pharmaceuticals$28.76-2.5%$34.34$13.57▼$43.72$529.15M1.2661,098 shs1.13 million shsVSTMVerastem$8.94-0.7%$8.60$2.54▼$11.24$553.91M0.891.76 million shs1.96 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHVAchieve Life Sciences+3.92%+11.29%+17.75%+48.07%-34.54%LXRXLexicon Pharmaceuticals-5.92%+1.42%+32.41%+26.55%-14.88%RIGLRigel Pharmaceuticals-2.51%+2.13%-29.63%+46.73%+83.18%VSTMVerastem-0.67%+1.59%-12.61%+88.61%+206.16%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHVAchieve Life Sciences$3.45+3.9%$2.90$1.84▼$5.31$169.67M1.58838,182 shs810,834 shsLXRXLexicon Pharmaceuticals$1.43-5.9%$1.19$0.28▼$2.18$552.37M1.232.67 million shs3.06 million shsRIGLRigel Pharmaceuticals$28.76-2.5%$34.34$13.57▼$43.72$529.15M1.2661,098 shs1.13 million shsVSTMVerastem$8.94-0.7%$8.60$2.54▼$11.24$553.91M0.891.76 million shs1.96 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHVAchieve Life Sciences+3.92%+11.29%+17.75%+48.07%-34.54%LXRXLexicon Pharmaceuticals-5.92%+1.42%+32.41%+26.55%-14.88%RIGLRigel Pharmaceuticals-2.51%+2.13%-29.63%+46.73%+83.18%VSTMVerastem-0.67%+1.59%-12.61%+88.61%+206.16%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACHVAchieve Life Sciences 2.75Moderate Buy$12.00247.83% UpsideLXRXLexicon Pharmaceuticals 2.29Hold$3.23125.52% UpsideRIGLRigel Pharmaceuticals 2.29Hold$38.2032.82% UpsideVSTMVerastem 2.80Moderate Buy$13.2948.61% UpsideCurrent Analyst Ratings BreakdownLatest ACHV, VSTM, LXRX, and RIGL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025ACHVAchieve Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025LXRXLexicon PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025RIGLRigel PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)10/8/2025RIGLRigel PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$57.0010/8/2025VSTMVerastemWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/6/2025RIGLRigel PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/27/2025ACHVAchieve Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025LXRXLexicon PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025RIGLRigel PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)9/27/2025VSTMVerastemWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/9/2025VSTMVerastemBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.00(Data available from 10/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACHVAchieve Life SciencesN/AN/AN/AN/A$0.61 per shareN/ALXRXLexicon Pharmaceuticals$58.43M8.89N/AN/A$0.40 per share3.58RIGLRigel Pharmaceuticals$179.28M2.88$1.05 per share27.34$0.19 per share151.37VSTMVerastem$10K55,016.76N/AN/A($0.65) per share-13.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACHVAchieve Life Sciences-$39.83M-$1.46N/AN/AN/AN/A-193.49%-116.68%11/6/2025 (Estimated)LXRXLexicon Pharmaceuticals-$200.40M-$0.33N/AN/AN/A-206.43%-83.63%-42.22%11/11/2025 (Estimated)RIGLRigel Pharmaceuticals$17.49M$5.415.3227.39N/A36.51%438.89%57.03%11/6/2025 (Estimated)VSTMVerastem-$130.64M-$3.28N/AN/AN/AN/AN/A-119.85%11/5/2025 (Estimated)Latest ACHV, VSTM, LXRX, and RIGL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/5/2025Q3 2025VSTMVerastem-$0.71N/AN/AN/AN/AN/A8/7/2025Q2 2025ACHVAchieve Life Sciences-$0.37-$0.37N/A-$0.37N/AN/A8/7/2025Q2 2025VSTMVerastem-$0.64-$0.39+$0.25-$0.39$6.01 million$2.14 million8/6/2025Q2 2025LXRXLexicon Pharmaceuticals-$0.08$0.01+$0.09$0.01$4.87 million$28.87 million8/5/2025Q2 2025RIGLRigel Pharmaceuticals$1.97$3.28+$1.31$3.28$64.58 million$101.69 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACHVAchieve Life SciencesN/AN/AN/AN/AN/ALXRXLexicon PharmaceuticalsN/AN/AN/AN/AN/ARIGLRigel PharmaceuticalsN/AN/AN/AN/AN/AVSTMVerastemN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACHVAchieve Life Sciences0.216.646.64LXRXLexicon Pharmaceuticals0.434.164.16RIGLRigel Pharmaceuticals0.462.021.90VSTMVerastem2.063.463.44Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACHVAchieve Life Sciences33.52%LXRXLexicon Pharmaceuticals74.70%RIGLRigel Pharmaceuticals66.23%VSTMVerastem88.37%Insider OwnershipCompanyInsider OwnershipACHVAchieve Life Sciences3.00%LXRXLexicon Pharmaceuticals13.90%RIGLRigel Pharmaceuticals9.48%VSTMVerastem2.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACHVAchieve Life Sciences2051.11 million49.57 millionOptionableLXRXLexicon Pharmaceuticals140363.40 million312.89 millionOptionableRIGLRigel Pharmaceuticals16017.94 million16.24 millionOptionableVSTMVerastem5061.54 million60.25 millionOptionableACHV, VSTM, LXRX, and RIGL HeadlinesRecent News About These CompaniesVerastem: Navigating Critical Steps In Commercialization And Development (Downgrade)October 7 at 12:10 AM | seekingalpha.comVerastem (NASDAQ:VSTM) Shares Up 4.9% - Still a Buy?October 7 at 1:44 PM | marketbeat.comVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 7 at 7:30 AM | businesswire.comVerastem, Inc. (NASDAQ:VSTM) Given Average Rating of "Moderate Buy" by BrokeragesOctober 6 at 2:37 AM | marketbeat.comVerastem (NASDAQ:VSTM) Stock Passes Above 200-Day Moving Average - Should You Sell?October 4, 2025 | marketbeat.comWall Street Zen Upgrades Verastem (NASDAQ:VSTM) to "Hold"September 21, 2025 | marketbeat.comVerastem (VSTM) Upgraded to Buy: Here's What You Should KnowSeptember 19, 2025 | zacks.comVerastem (NASDAQ:VSTM) Trading Up 5.6% - Still a Buy?September 18, 2025 | marketbeat.comVerastem, Inc. $VSTM Shares Acquired by Goldman Sachs Group Inc.September 18, 2025 | marketbeat.comTop Biotech Picks for 2025: BTIG Research Highlights Potential WinnersSeptember 16, 2025 | finance.yahoo.comVerastem (NASDAQ:VSTM) Lowered to Sell Rating by Wall Street ZenSeptember 15, 2025 | marketbeat.comVerastem, Inc. (NASDAQ:VSTM) Given Consensus Rating of "Buy" by AnalystsSeptember 13, 2025 | marketbeat.comVerastem (NASDAQ:VSTM) Trading Down 7.6% - Should You Sell?September 12, 2025 | marketbeat.comBTIG Research Reaffirms Buy Rating for Verastem (NASDAQ:VSTM)September 11, 2025 | marketbeat.comOctagon Capital Advisors LP Invests $10.37 Million in Verastem, Inc. $VSTMSeptember 11, 2025 | marketbeat.comVerastem’s Promising KRAS G12D Inhibitor VS-7375: A Buy Rating Backed by Strong Clinical Data and Strategic OutlookSeptember 9, 2025 | tipranks.comPolar Asset Management Partners Inc. Invests $300,000 in Verastem, Inc. $VSTMSeptember 9, 2025 | marketbeat.comLeerink says competitor data suggest promising view for Revolution’s zoldonrasibSeptember 8, 2025 | msn.comVerastem Updates on Cancer Therapy DevelopmentsSeptember 8, 2025 | tipranks.comVerastem Oncology to Present at Upcoming Investor ConferencesAugust 27, 2025 | mms.businesswire.comVerastem’s Promising Phase 3 Trial in Ovarian Cancer: A Potential Game-Changer?August 25, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACHV, VSTM, LXRX, and RIGL Company DescriptionsAchieve Life Sciences NASDAQ:ACHV$3.45 +0.13 (+3.92%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$3.44 -0.01 (-0.29%) As of 10/8/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.Lexicon Pharmaceuticals NASDAQ:LXRX$1.43 -0.09 (-5.92%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$1.44 +0.02 (+1.05%) As of 10/8/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.Rigel Pharmaceuticals NASDAQ:RIGL$28.76 -0.74 (-2.51%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$28.70 -0.06 (-0.19%) As of 10/8/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.Verastem NASDAQ:VSTM$8.94 -0.06 (-0.67%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$9.07 +0.13 (+1.45%) As of 10/8/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Archer Aviation Stock Is Soaring—And What Comes Next Lithium Americas: Why This 31% Rally Is More Than Just a Headline Energy Transfer's New Growth Engine Ignites Investor Interest AMD Could Double From Here—Thanks to Its Blockbuster OpenAI Deal AMD and OpenAI: A Partnership That Just Redrew the AI Map EA’s $55 Billion Deal Spurs a Shake-Up in the Gaming Sector 3 Dividend Aristocrats to Buy Before Year’s End Falcon Flex Drives Growth as CrowdStrike Bets on AI Security Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
